Bioblast 2022: Inaugural Conference of Bioenergetics Communications
2022-06-29 - 2022-06-30 | Congress Innsbruck, Rennweg 3, Innsbruck, Austria
On June 29-30, Abliva will participate at Bioblast 2022: Inaugural Conference of Bioenergetics Communications in Innsbruck, Austria.
Abliva’s Communications Officer & Lab Manager, Eleonor Åsander Frostner, will present a summary of the company’s recent preprint publication “Towards a treatment for mitochondrial disease: current compounds in clinical development“.

UMDF's Mitochondrial Medicine Symposium
2022-06-08 - 2022-06-11 | JW Marriott Phoenix Desert Ridge Resort & Spa, Phoenix, AZ, United States
Abliva will participate at the United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium in Phoenix, Arizona.
Abliva’s CMO, Magnus Hansson, will participate in a panel discussion on clinical trials together with Baylor College of Medicine, Cyclerion Therapeutics, and Khondrion, on Friday June 10.

Mitochondria-Targeted Drug Development Summit
2022-02-22 - 2022-02-24 | Hyatt Regency Boston/Cambridge, 575 Memorial Dr, Cambridge, Massachusetts, 02139, United States
Abliva will attend and present at the Mitochondria-Targeted Drug Development Summit in Boston, MA, USA. The event will be held on 22 – 24 February 2022.
CEO Ellen Donnelly will be presenting in the session Patient-Focused Drug Development for Mitochondrial Disease.
Synopsis:

Highlighting the impact of patient input on research and development at Abliva
Providing an overview of the multiple therapeutic options for mitochondrial disease being pursued at Abliva
Presenting placebo controlled PMD patient data from our lead asset, KL1333

Mitochondrial Medicine - Therapeutic Development
2021-11-30 - 2021-12-02 | Virtual
Abliva will attend the virtual conference Mitochondrial Medicine – Therapeutic Development, organized by the Wellcome Connecting Science located at the Wellcome Genome Campus in the UK, on 30 Nov – 2 Dec 2021.
Abliva’s CMO, Magnus Hansson, has been invited to give a presentation on the topic Academia-pharma interplay in drug development, during Session 1: Mitochondrial Medicine – pharma and funding perspectives.

Mitochondrial Diseases Conference 2021
2021-10-15 - 2021-10-16 | Virtual
Italian patient organization Mitocon arranges this year’s Mitochondrial Diseases Conference in virtual.
Abliva’s Chief Medical Officer, Magnus Hansson, will give a flash presentation and join round table discussions at the meeting.

UMDF Mitochondrial Medicine
2021-06-24 - 2021-06-26 | Virtual
The US patient organization United Mitochondrial Disease Foundation (UMDF) is hosting its annual Mitochondrial Medicine Symposium, this year virtual, in June.
Abliva will participate in the scientific sessions:

Chief Medical Officer, Magnus Hansson, will constitute one of the panelists, on Friday 25 June, at 1:50 p.m. EST, in the Clinical Trials Panel #2 Discussion, together with representatives from Baylor College of Medicine, Cyclerion Therapeutics, and Khondrion.
Data from Abliva’s Phase 1a/b study with KL1333 will be presented on an e-Poster, available to registered participants throughout the event.
